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Abstract 
Impaired angiogenesis is a major clinical problem and affects wound healing 
especially in diabetic patients. Improving angiogenesis is a reasonable strategy to 
increase diabetes-impaired wound healing. Recently, our lab described a system of 
transient gene expression due to pegylated poly-L-lysine (PLL-g-PEG) polymer-
mediated plasmid DNA delivery in vitro. Here we synthesized peptide-modified PLL-
g-PEG polymers with two functionalities, characterized them in vitro and utilized 
them in vivo via a fibrin-based delivery matrix to induce dermal wound angiogenesis 
in diabetic rats. The two peptides were 1) a TG-peptide to covalently bind these 
nanocondensates to the fibrin matrix (TG-peptide) for a sustained release and 2) a 
polyR peptide to improve cellular uptake of these nanocondensates. In order to induce 
angiogenesis in vivo we condensed modified and non-modified polymers with 
plasmid DNA encoding a truncated form of the therapeutic candidate gene hypoxia-
inducible transcription factor 1α (HIF-1α). HIF-1α is the primarily oxygen-dependent 
regulated subunit of the hetero-dimeric transcription factor HIF-1, which controls 
angiogenesis among other physiological pathways. The truncated form of HIF-1α 
lacks the oxygen-dependent degradation domain (ODD) and therefore escapes 
degradation under normoxic conditions. PLL-g-PEG polymer mediated HIF-
1α−ΔODD plasmid DNA delivery was found to lead to a transiently induced gene 
expression of angiogenesis related genes Acta2 and Pecam1 as well as the HIF-1α 
target gene Vegf in vivo. Furthermore, HIF-1α gene delivery was shown to enhance 
the number endothelial cells and smooth muscle cells – precursors for mature blood 
vessels – during wound healing. We show that – depending on the selection of the 
therapeutic target gene – PLL-g-PEG nanocondensates are a promising alternative to 
viral DNA delivery approaches, which might pose a risk to health. 
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1. Introduction 
Wound healing is a highly dynamic process comprising several overlapping stages: 
haemostasis/inflammation, migration, proliferation and maturation phases. It involves 
complex interactions of extracellular (ECM) molecules, soluble mediators, various 
resident cells and infiltrating cells to achieve the goal of tissue integrity [1]. Diseases 
such as diabetes mellitus interfere with wound healing by disrupting the orderly 
sequence of events at one or more of the stages, thereby compromising the wound 
healing process. The deficiency of endogenous growth factors [2, 3] and/or the 
excessive production of exudates and expression of high levels of tissue destructive 
proteinases [4] are associated to chronic wound formation. Diabetic ulcerations are 
characterized by impaired neovascularization and blood perfusion. Approximately 5 
to 15% of diabetes patients are prone to foot ulcer development [5], requiring an 
appropriate strategy to improve wound healing. 
Gene therapy has gained increasing attention as an alternative approach for wound 
treatment [6-8]. Especially non-viral gene transfer benefits from biosafety and the 
unlimited gene size transportation capacity [9]. However, the major drawbacks of 
non-viral vectors are their poor in vivo transfection efficiencies resulting in low 
protein production, as well as their transient gene expression profile, which for 
improvement of local and temporal wound healing, is desirable. Therapeutic DNA is 
able to condense with poly-cationic substances such as poly-L-lysine (PLL), poly-L-
ornithin or polyethylenimine (PEI) [10-13]. Polymers with high cationic density 
confer cytotoxicity [14], which is circumvented by the formation of different block-
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copolymers between poly(ethylene glycol) (PEG) and PLL, PEI or poly-aspartic acid 
[10, 13-15]. Polymer-DNA condensates using grafted copolymers of PLL and PEG 
have been shown to combine low cytotoxicity, stealth properties and high transfection 
efficiency in COS-7 cells [16, 17], suggesting that they are a promising tool for 
effective transport and delivery of therapeutic DNA. 
An excellent candidate protein to support wound revascularization is the transcription 
factor hypoxia-inducible factor 1 (HIF-1). Among other physiological pathways, HIF-
1 controls angiogenesis by regulating the expression of pro-angiogenic target genes 
including Vegf-a [18]. HIF-1 is an oxygen-responsive, heterodimeric transcription 
factor consisting of an alpha-subunit and a beta-subunit. In order to quickly react to 
changes in oxygen concentrations, both subunits are constitutively expressed with 
HIF-1α being posttranslationally regulated by oxygen availability. Prolylhydroxylases 
(PHDs) hydroxylate HIF-1α at two specific proline residues that are located in the 
oxygen-dependent degradation domain (ODD)	   [19-21] in an oxygen-dependent 
manner. This targets HIF-1α for the binding of the tumor suppressor von-Hippel-
Lindau protein (VHL), which initiates the accumulative binding of ubiquitin and 
eventually leads to proteasomal degradation of HIF-1α [22]. Additionally, factor 
inhibiting HIF (FIH) hydroxylates human HIF-1α subunits at an asparagine residue in 
the C-terminal transactivation domain. This interferes with the binding of the essential 
transcriptional co-activators p300 and CBP (CREB binding protein) and reduces the 
transcriptional activity of HIF-1 [23]. An engineered variant of HIF-1α, which lacks 
the ODD, escapes the oxygen-dependent degradation – resulting in stable expression 
under normoxic conditions. Recently, condensates of HIF-1α−ΔODD plasmid DNA 
and peptides were shown to increase the number and the quality of newly formed 
blood vessels in full thickness excision dermal wounds of healthy mice after release 
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from modified 3D-fibrin matrices [24]. Fibrin hydrogels harbor a great wound healing 
potential. They are among the most often used native hydrogels to induce 
angiogenesis and wound healing per se [25, 26] and have been widely used as a drug 
delivery system [27, 28]. 
Since the formation of new blood vessels is a prerequisite for successful wound 
healing, we tested whether PLL-g-PEG based polymers deliver potentially therapeutic 
HIF-1α−ΔODD plasmid DNA and induce blood vessel formation in vivo. Thus, we 
produced and employed 3D-Fibrin matrices as release system for the local gene 
therapeutic approach and analyzed the effect of HIF-1α−ΔODD plasmid DNA 
delivery on wound revascularization under normal and diabetic conditions in vivo. 
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2. Materials and Methods 
 
2.1. Nomenclature of PLL-g-PEG polymers 
Three different PLL-g-PEG polymers were used in this study (Fig. 1) consisting of a 
20 kDa poly-L-lysine (PLL) backbone grafted with 5 kDa poly(ethylene glycol) 
(PEG). Grafting density (g) indicates the percentage of pegylated lysine residues. TG 
and polyR abbreviate peptide sequences encoding either a transglutaminase 
recognition sequence allowing covalent incorporation of the polymer into fibrin 
hydrogels (TG-peptide) or a nuclear translocation sequence facilitating nuclear 
polymer uptake (polyR-peptide). 
2.2. PLL-g-PEG polymer synthesis 
The synthesis of unmodified PLL20-g5-PEG5 was previously described by Pasche and 
coworkers and by Rimann et al.	  [17, 29]. 
For PLL20-g8-PEG5-TG synthesis, 26 mg NHS-PEG-Mal (4750 g/mol, IRIS, 
PEG1063) was mixed with the 29.6 mg N-terminal Fmoc-protected TG peptide 
NQEQVSPLGYERCG (GenScript Corporation, Piscataway, NJ, USA) in 500 µl 
DMSO at room temperature. Further, 20 mg PLL20 (20 kDa, Sigma, P7890) was 
dissolved in 90 µM trieethylamine containing DMSO and added drop-wise into the 
aforementioned solution, allowing a reaction over night at room temperature. After 
adding 8 ml H2O the solution was dialyzed against ddH2O at 4 °C, lyophilized and 
analyzed by 1H-NMR in D2O (supplemental data Fig.1). To remove the Fmoc 
protection, the PLL20-g8-PEG5-TG-Fmoc construct was dissolved in 20% piperidine 
and 80% DMF and reacted at room temperature for 1 h. After adding 17 ml H2O the 
product was again dialyzed against H2O. After filtering and lyophilization the product 
was verified by 1H-NMR in D2O (supplemental data Fig.2 I). 
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PLL20-g3-PEG5-polyR was synthesized using 13 mg NHS-PEG-Mal and 10mg PLL20 
- each dissolved in 0.1 M phosphate buffer. Both solutions were mixed and incubated 
for 1 h at room temperature. 14.6 mg of the polyR peptide dissolved in phosphate 
buffer were added and reacted over night at room temperature. The product was 
dialyzed against water, lyophilized and characterized by 1H-NMR in D2O 
(supplemental data Fig.2 II). 
2.3. Formulation of PLL-g-PEG-DNA nanocondensates 
To form polymer-DNA nanocondensates we used plasmid DNA expressing either 
EGFP (pEGFP-N1) or a form of HIF-1α lacking the oxygen dependent degradation 
domain (pHIF-1α−ΔODD). To simplify nomenclature the condensates were given 
abbreviations (Table 1).  As previously described, 1 µg plasmid DNA was condensed 
with PLL20-g5-PEG5 (N/P ratio 3.125) [17]. Likewise, 1 µg plasmid DNA was 
condensed with PLL20-g5-PEG8-TG or PLL20-g5-PEG3-polyR with N/P ratios ranging 
from 1 to 25 in order to find the optimal ratio for transfection. For all subsequent 
experiments the N/P ratio 6.25 was used. The hydrodynamic diameter of the 
nanocondensates was determined by dynamic light scattering as previously described 
[17]. 
2.4. Cell Culture and In vitro Transfection 
COS-7 cells were cultured in 1 g/l glucose containing DMEM (Gibco), supplemented 
with 10% FBS (Sigma) and 1% Pen/Strep (Sigma) at 37°C and 5% CO2. To mimic a 
high-glucose environment, cells were adapted to 4.5 g/l glucose containing DMEM 
medium (Gibco) for 4 weeks	  [30]. Polymer-DNA condensates were produced and 
applied as described by Rimann et al. [17]. 
2.5. Cell Viability Assay 
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WST-1 assay (Roche) was used to determine the viability of COS-7 cells after 
transfection with polymeric nanocondensates under normal and high-glucose 
conditions. Fresh growth medium was added on cells followed by addition of 50 µl 
WST-1 reagent. After incubation at 37°C for 1 hour, the absorbance was detected by a 
TECAN Infinite M200 microplate reader at 440 nm wavelength. The cell viability 
was assessed by normalization to non-treated cells. 
2.6. 3D Fibrin Hydrogels 
For in vitro release assays 200 µl fibrin hydrogels were produced containing 2 mg/ml 
fibrinogen (Sigma), 1 U/ml factor XIII, 1.25 mM CaCl2 and 5 U/ml thrombin 
(Sigma). Each fibrin gel contained either 2 µg naked pEGFP-N1 plasmid DNA or 
nanocondensates with a total amount of 2 µg pEGFP-N1 plasmid DNA. For in vivo 
wound healing studies 100 µl fibrin hydrogels per wound were produced consisting of 
10 mg/ml fibrinogen, 2 U/ml factor XIII, 1.25 mM CaCl2 and 7.5 U/ml thrombin. 
Such hydrogels further contained either 1 µg recombinant human VEGF165 
(Peprotech), PLL20-g5-PEG5/pHIF-1α−ΔODD (-/HIF), PLL20-g8-PEG5-TG/pHIF-
1α−ΔODD (TG/HIF) or PLL20-g3-PEG5-polyR/pHIF-1α−ΔODD (polyR/HIF). 
2.7. In vitro release from 3D fibrin hydrogels 
Polymer-DNA containing hydrogels were covered with PBS and incubated at 37° C 
and 5% CO2 while gently shaking. Nanocondensate release was monitored for 7 days 
and PBS supernatant was removed and replaced in a 24-hour cycle. To determine the 
amount of released DNA supernatant were treated with NaOH to release DNA from 
the positively charged polymers and DNA was quantified by PicoGreen dsDNA 
reagent (Invitrogen) according to manufactures protocol. To determine the 
functionality of the released nanocondensates COS-7 cells were incubated with 200 µl 
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supernatant for 48 hours and transfection efficiency was determined by EGFP 
expression. 
2.8. Animals 
Animals were treated in accordance with the regulations of the Swiss Veterinary 
Authority of Zurich. Sprague Dawley rats (Crl:CD(SD) Charles River, Germany) 
weighing 180 to 220 g were kept pair wise in a 12 h light/dark cycle at 22°C and 50% 
humidity. Diabetes mellitus type I was induced by a single, intravenous injection of 
65 mg/kg streptozotocin (STZ) (Sigma). Control animals received a Mock-injection 
of the respective solvent 0.1M sodium citrate buffer (pH 4.5). Blood glucose levels 
were measured with a glucometer (Roche, Accu-Chek Aviva) by puncturing the tail 
tip. Blood glucose levels higher than 16.7 mM 3 days after injection were considered 
to be diabetic. STZ-treated animals with blood glucose levels below 16.7 mM 
received a second injection of STZ. 
2.9. Full-thickness excision wound preparation 
1 week after receiving STZ- or Mock-injection rats were anesthetized by isoflurane  
(Attane, Minrad Inc., Buffalo, USA) and received a single 5 mg/kg subcutaneous 
injection of Carprofen (Rimadyl, Pfizer AG, Zurich, Switzerland). After shaving the 
dorsal region, 10 mm diameter full-thickness wounds were generated with a small 
round scissor. The wounds were filled with 100 µl fibrin hydrogel containing 
VEGF165 or nanocondensates. Fibrin-only hydrogels served as negative control. Fibrin 
hydrogels were covered with a dressing (Opsite Flexigrad, Smith & Nephew) and 
fixed with a tape (Leukotape Claassic, Smith & Nephew). Animals were sacrificed 3 
and 7 days post injury by pneumothorax generation with prior anesthesia in 4% 
isoflurane. Wounds were isolated and bisected. One half was immediately frozen in 
liquid nitrogen for RNA and protein isolation. The second half was fixed by 4% PFA 
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(Acros Organics) in MB buffer (65 mM PIPESm, 25 mM HEPES, 10 mM EGTA, 3 
mM CaCl2, pH 6.9) for 24 hours. For immunohistological analyses wounds were 
embedded in paraffin and cut into 7 µm sections. 
2.10. Immunohistological Analyzes 
Paraffin sections were rehydrated followed by an antigen-retrieval treatment in citrate 
buffer (pH 6, 0.05% Tween20) for 15 min at 98°C.  After blocking with 1% BSA 
sections were incubated with primary antibodies CD31 (Santa Cruz, 1:50; R&D, 
AF3628, 1:500) and SMA (Abcam, 1:100) over night. Sections were washed and 
Alexa 488 and Alexa 546 labeled secondary antibodies (Molecular Probes) were 
applied followed by a DAPI (Molecular Probes) staining. After mounting with 
Moviol (Calbiochem) samples were microscopically analyzed. Blood vessel structures 
were quantified blinded with image J and manual counting. 
2.11. Real-time PCR 
Total RNA was extracted using the RNeasy isolation kit (Qiagen, Hilden, Germany) 
with a prior proteinase K digestion (Qiagen, Hilden, Germany) and including a DNase 
treatment to remove residual genomic DNA. cDNA was prepared from equal amounts 
of total RNA using oligo(dT) primers and M-MLV reverse transcriptase (Promega, 
Madison, WI, USA). 10 ng of cDNA was amplified in a StepOnePlusTM Real-Time 
PCR System (Applied Biosystems) using TaqMan® Gene Expression Master Mix 
(Applied Biosystems) and appropriate probes (Applied Biosystems) (Table 2). cDNA 
levels were normalized to Rpl13a [31] and relative values were calculated using a 
respective calibrator. At least six independent samples were used for each condition. 
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3. Results 
3.1. Characterization of PLL-g-PEG polymers 
PLL-g-PEG forms stable nanocondensates with plasmid DNA, which successfully 
transfect cells in vitro [17]. To equip such polymers with additional features, we 
conjugated two specific peptides, namely polyR and TG (transglutaminase 
recognition sequence), to the distal end of the PEG molecules (Fig.1.B) in order to 
increase transfection efficiency or to covalently bind such polymers to a fibrin matrix, 
respectively. The size of DNA-polymer condensates critically determines the cellular 
uptake [16, 24, 32]. To predict the correlation of polymer modification with peptides 
and the polymer-DNA condensate size, we used dynamic light scattering (DLS) to 
measure the hydrodynamic diameter. In combination with DNA, unmodified PLL-g-
PEG polymers form condensates with a mean diameter of 90 nm (Fig.2.A). Both 
modified polymers form spheric nanocondensates with hydrodynamic diameters of 
102 and 112 nm respectively (Fig.2.A), suggesting that the condensate size is slightly 
affected by the peptide-functionalization. With an NH4+/PO43- (N/P) ratio of 3.125, 
unmodified PLL-g-PEG condensates display an optimal compromise between high 
transfection efficiency and low cytotoxicity [17]. To determine the effect of the N/P 
ratio in peptide-linked polymer-DNA condensates, we analyzed the in vitro 
transcription efficiency in COS-7 cells using an enhanced GFP expressing vector 
(eGFP) (Fig.2.B). At N/P ratios of 3.125 or lower both, TG and polyR, modified 
polymers showed a poor transfection efficiency when compared to unmodified 
control polymers. With increasing N/P ratio of 6.25 or more, both polymers obtained 
improved transfection efficiency. TG-modified nancondensates (TG/GFP) reached 
similar transfection efficiencies when compared to unmodified nanocondensates (-
/GFP) [17] and polyR-modified nanocondesates (polyR/GFP) exceeded the 
	   13	  
transfection efficiency of -/GFP by factor 2. This indicates that the TG peptide does 
not negatively affect transfection whereas the polyR functionalization effectively 
enhances the transfection efficiency of PLL-g-PEG based nanocondesates. Since N/P 
ratios higher than 6.25 decrease cell survival [17], all further experiments were 
conducted with a N/P ratio of 6.25 for both, TG and polyR functionalized polymers, 
combining efficient transfection with low cytotoxicity as previously described	  [12, 16, 
17]. 
To analyze whether diabetic conditions may influence the cellular uptake of PLL-g-
PEG -DNA condensates, we pre-adapted COS-7 cells for four weeks in a high and 
low glucose environment to mimic diabetic and control conditions in vitro [30]. Our 
results indicate that the in vitro transfection efficiency of the different PLL-g-PEG 
polymers is comparable under high and low glucose conditions (Fig.2.C) suggesting 
that diabetes-like glucose levels have no effect on nanocondensate uptake. To predict 
the cytotoxicity of modified PLL-g-PEG polymers under high and low glucose 
conditions, we analyzed the cell viability of COS-7 cells. All different 
nanocondensates, with a N/P ratio of 6.25 for modified and a N/P ratio of 3.125 for 
unmodified polymers, display a high cell viability of 90 to 100% under both, normal 
and high glucose conditions (Fig.2.D). 
Hence, the in vitro characterization of peptide-functionalized PLL-g-PEG polymers-
DNA condensates suggests that such condensates have improved transfection 
efficiency and low cytotoxicity, which is independent of the glucose environment. 
 
3.2. Release pattern of PLL-g-PEG polymers from fibrin matrices 
To analyze whether TG functionalized PLL-g-PEG polymers are covalently 
incorporated into a 3D delivery network, we embedded PLL-g-PEG -TG/pEGFP-N1 
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(TG/GFP) (N/P 6.25) and PLL-g-PEG/pEGFP-N1 (-/GFP) (N/P 3.125) 
nanocondensates into fibrin matrices and monitored their release over a period of 7 
days with naked DNA serving as a control. Nanocondensate-containing fibrin 
matrices were incubated with PBS and the release was quantified by DNA 
measurements to determine the release kinetics. Plain DNA and -/GFP were 
progressively released from fibrin matrices into the supernatant (Fig.3.A). With a 
relative release of 67% after 7 days, plain DNA displayed higher release kinetics than 
-/GFP with 46% after 7 days. In contrast, TG/GFP remained entrapped within the 
fibrin matrix suggesting that these nanocondensates were covalently incorporated. 
Additionally, the recognition and cross-linking of PLL-g-PEG -TG nanocondensates 
by factor XIIIa was confirmed by MAPL analysis (supplemental data Fig. 3). 
To determine whether embedding into the fibrin matrix affects the integrity and 
functionality of PLL-g-PEG nanocondensates, we performed transfection studies with 
PBS supernatant containing the released nanocondensates. -/GFP was able to transfect 
COS-7 cells within the first 5 days (Fig.3.B) with 50% efficiency of non-embedded 
control samples suggesting that released nanocondensates remained intact. After day 
6 the transfection efficiency was decreased which correlates with the reduced release 
of -/GFP nanocondensates at day 6 and 7. Released naked DNA and supernatants of 
TG/GFP containing matrices showed no transfection of COS-7 cells.  
PLL-g-PEG nanocondensates can be successfully embedded into a 3D fibrin delivery 
matrix and maintain their functionality after progressive release. 
 
3.3. Diabetes mellitus type I induction in rats 
To test whether the treatment with different PLL-g-PEG -DNA condensates encoding 
a stable form of HIF-1α (HIF-1α−ΔODD) affects wound angiogenesis of normal and 
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diabetic rats we used streptozotocin (STZ) to induce diabetes mellitus type 1. Rats 
received either STZ (65 mg/kg) or a respective mock injection. STZ- but not Mock-
treated animals showed rising levels of blood glucose between 3 and 5 days post 
injection – reaching and maintaining a plateau (supplemental data Fig. 3). Typically 
for diabetic rats, STZ-treated animals showed in addition reduced gain in body weight 
over the same time period (supplemental data Fig. 3). Both parameters showed that 
the diabetic phenotype was successfully established. 
 
3.4. Gene expression after HIF-1α−ΔODD gene delivery 
HIF-1α encodes for the primarily oxygen dependent regulated subunit of the hetero-
dimeric transcription factor HIF-1, which controls angiogenesis among other 
physiological pathways. 
To assess whether the delivery of stable HIF-1α−ΔODD with different PLL-g-PEG 
polymers affects gene expression, we analyzed mRNA levels of the typical HIF-1 
downstream target gene Vegf (Fig.4.A first row diagrams) 3 and 7 days post surgery. 
With -/HIF condensates performing the best, all nanocondensates induced Vegf gene 
expression in Mock treated animals (1.5 to 2 fold) compared to fibrin only treated 
wounds (negative control) and VEGF165 protein treated positive controls suggesting 
that HIF-1α−ΔODD was successfully delivered. In contrast, STZ treated animals 
showed only slightly induced Vegf mRNA levels. In addition, we analyzed the 
expression of genes especially expressed by cells giving rise to new blood vessels. 
Pecam1 encodes for CD31 – a typical endothelial cell marker and Acta2 encodes α-
SMA – a marker for smooth muscle cells and myofibroblasts that are involved in 
wound contaction. Pecam1 (Fig.4.A. second row of diagrams) was induced in Mock- 
treated animals by wound treatment with -/HIF, TG/HIF and polyR/HIF 3 and 7 days 
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after surgery. VEGF165 protein application slightly induced Pecam1 in Mock-treated 
wounds 7 but not 3 days after injury. Again, STZ-treated animals showed only a 
minor induction of gene expression 7 days after surgery. Acta2 gene expression 
(Fig.4.A. third row) was slightly induced after nanocondensate treatment in Mock 
treated animals, but not after VEGF165 protein delivery. 
 
3.5. The angiogenic response to HIF-1α−ΔODD gene delivery 
HIF-1α gene delivery has been shown to promote wound healing and angiogenesis 
[33]. Our newly established PLL-g-PEG -DNA condensates are able to successfully 
deliver a HIF-1α expression system in vivo to initiate differential expression of 
angiogenesis-related genes. To test whether wound revascularization can be improved 
by such a treatment we immunohistochemically visualized and quantified endothelial 
cells and smooth muscle cells (α-SMA positive) in wounds of Mock- and STZ-treated 
rats 3 and 7 days after surgery (Fig.5.A.). In 3-day-old wounds we observed neither a 
difference in endothelial cell number (CD31 positive) nor in smooth muscle cells 
when comparing fibrin treated control wounds with PLL-g-PEG-HIF-1α−ΔODD or 
VEGF165 treated wounds (supplemental data Fig. 4). 7 days post surgery 
nanocondensate treatments seem to induce the number of CD31 positive endothelial 
cells to approximately 150% in Mock-treated animals, suggesting an accelerated 
recruitment and/or proliferation of endothelial cells (Fig.5.B a) under normal 
conditions. However, wounds of STZ-induced animals displayed even a minor 
reduction of CD31 signals after nanoncondensate treatment – especially in polyR/HIF 
treated wounds. In line with these findings, we found smooth muscle actin positive 
cells induced by the different polymer-DNA condensates in normal animals but not in 
diabetic animals (Fig.5.B b). Since both – endothelial cells and smooth muscle cells – 
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participate in blood vessel formation, we counted CD31/SMA double positive signals 
in order to quantify maturely formed blood vessels. We found that VEGF protein, a 
potent inducer of angiogenesis, rather reduced the number of blood vessels in wounds 
of healthy animals. Furthermore, we found no difference in double stained structures 
and hence no increased number of mature blood vessels in Mock- as well as in STZ-
treated animals (Fig.5.B c) 7 days post injury although both markers – CD31 and 
SMA – were induced after polymer-DNA treatment. That suggests that the increased 
smooth muscle actin positive cells may be rather myofibroblasts cells in a transition 
state between fibroblasts and smooth muscle cells than mature smooth muscle cells 
participating in vessel formation. Due to the observed elevated number of endothelial 
cells – contributing to blood vessels – and potential myofibroblasts that may 
contribute to wound contractility, we also determined the total cell number per wound 
area (Fig.5.B d) as well as the wound thickness (Fig.5.B e). However, except for 
reduction in polyR/HIF treated wounds of diabetic animals we found that neither the 
polymer-DNA condensates nor VEGF protein affected the total cell number – and 
hence proliferation or migration, respectively – per wound area. Additionally, the 
wound thickness was hardly affected in Mock treated animals. Surprisingly, under 
diabetes mimicking conditions polyR/HIF as well as the positive control VEGF 
seemed to repress instead of accelerate wound contraction. This, in combination with 
the reduced blood vessels after VEGF165 application (Fig.5.B c), suggests that higher 
levels of VEGF – either applied or endogenously expressed – may even interfere with 
wound healing. 
 
3.6. The impact of HIF-1α−ΔODD gene delivery on the capillary network 
Both, VEGF165 protein application as well as polymer-HIF-1α-DNA condensates, are 
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able to successfully induce blood vessel precursor cells but fail to induce mature 
blood vessels 7 days post injury. To estimate whether nanocondensate-mediated HIF-
1α−ΔODD delivery affects the capillary network formation, we measured the 
diameter of blood vessels 7 days after surgery. The majority of capillaries in fibrin 
only treated wounds had a diameter of 4 – 8 µm (Fig.6.A.) with an average of 7 µm 
(Fig.6.B.). VEGF165- and both nanocondensate- (-/HIF and TG/HIF) treatments 
increased the prevalence of smaller capillaries ranging between 2 and 6 µm in Mock 
treated animals (Fig.6.A.) resulting in a smaller average diameter of 5.8 to 6.5 µm 
(Fig.6.B.). A similar effect was observed in STZ-injected animals after -/HIF and 
TG/HIF treatment. However, VEGF165 protein application into wounds of STZ-
injected animals had no effect on the average blood vessel diameter when compared 
to fibrin-control wounds (Fig.6.B.). Wounds treated with polyR/HIF showed neither 
under normal nor under diabetic conditions an effect on blood vessel size.  
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4. Discussion 
Wound revascularization depends on the precisely balanced interplay of several 
proangiogenic growth factors like VEGF and PDGF [34] and on a proper growth 
factor gradient [35] to direct blood vessel growth. Therefore, a protein therapy might 
be disadvantageous because locally administered proteins experience rapid dilution 
and degradation processes [36], which may cause an inhomogeneous gradient. Instead 
of the local administration of expensive protein cocktails, we established and used a 
system to deliver therapeutic DNA encoding a modified version of the alpha subunit 
of HIF-1, which escapes normoxic degradation due to the lack of its oxygen-
dependent degradation domain (ODD) [22]. HIF-1 controls the expression of several 
proteins required for the induction and correct assembly of blood vessels [18] and has 
been shown to improve wound healing [33, 37, 38]. Since excessive over-expression 
of the HIF-1α subunit may correlate with pathophysiological tissue alteration and 
cancer growth [39], it is essential to temporarily control the expression pattern and to 
adapt it to the demand of the clinical situation. Here we established a PLL-g-PEG 
polymer-based gene delivery system as a therapeutic approach to transiently and 
safely alter HIF-1α expression levels. We employed previously characterized PLL-g-
PEG based polymer with an optimized balance of low cytotoxicity, stealth properties 
and high cellular DNA-nanocondensate uptake [16, 17] and modified them with 
surface-functionalizing peptides for an in vivo application. We characterized them in 
vitro and tested them in vivo to explore their therapeutic potential under normal and 
diabetic conditions in a wound healing study. 
Pegylation provides stealth properties and the possibility to conjugate functional 
modules to distal moieties of nancondensates. The polymers were surface-
functionalized with either a fusogenic peptide consisting of 6 arginine residues 
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(polyR) to facilitate cellular uptake and transport through cellular compartments or a 
factor XIIIa transglutaminase substrate (TG) sequence allowing a covalent 
incorporation into fibrin wound-healing matrices [33]. TG and PolyR functionalized 
PLL-g-PEG-DNA condensates displayed a hydrodynamic diameter of 102 to 112 nm, 
suggesting that the condensates were slightly bigger than non-modified PLL-g-PEG-
DNA condensates (90 nm) [17] but still displayed an appropriate size for cellular 
uptake [24, 32]. The nuclear uptake facilitating polyR peptide modification of PLL-g-
PEG (N/P 6.25) improved the transfection rate of factor 2 in vitro when compared to 
unmodified PLL-g-PEG nanocondensates. The TG peptide covalently bound to fibrin 
and allows fibrin-embedded PLL-g-PEG–DNA condensates to remain entrapped 
within the matrix until matrix degradation occurs without losing their transfection 
efficiency. Both peptide modified PLL-g-PEG condensates displayed low cytotoxicity 
comparable to unmodified polymers [17]. Furthermore, unmodified and modified 
polymers maintained their transfection efficiency of COS-7 cells in a high glucose 
environment suggesting that a potential diabetic environment may not alter cellular 
uptake. 
PLL-PEG nanocondensates have been shown to successfully deliver therapeutic 
plasmid DNA in vivo	  [40]. We employed our different PLL-g-PEG condensates in 
vivo to explore their pro-angiogenic therapeutic potential in a diabetic wound-healing 
model [41]. To progressively release the nanocondensates to the side of injury, we 
used fibrin matrices and embedded functionalized PLL-g-PEG polymers that 
condensed HIF-1α−ΔODD [22] plasmid DNA. Analyzing mRNA gene expression 
after wound treatment, we found that the HIF-1 downstream target gene Vegf was 
induced by polymer-DNA condensates in wounds of non-diabetic animal 3 and 7 days 
post injury. Especially unmodified PLL-g-PEG and PLL-g-PEG-TG polymers 
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displayed elevated Vegf mRNA levels indicating that HIF-1α was successfully 
delivered to the side of injury. The fact that the expression levels returned back to 
normal levels at a later stage of wound healing (7 days; Fig.4.) indicates that HIF-1α 
is indeed only transiently induced and experiences a progressive down regulation. 
PolyR modified PLL-g-PEG polymers, which showed the best transfection efficiency 
in vitro, induced the Vegf mRNA expression in vivo but did not further improve the 
elevated expression levels of unmodified or TG-modfied nanocondensates. In contrast 
to healthy animals, the nanocondensates failed to significantly induce Vegf gene 
expression in diabetic animals, although high glucose adapted COS-7 cells showed no 
reduced nanocondensate uptake in vitro. It seems that HIF-1α, although a sustained 
expression can improve wound healing and revascularization in normal [33] and 
diabetic mice [42], is more rapidly degraded [43] and displays a reduced activity 
under hyperglycemic conditions [30, 44] due to the methylglyoxylation of its 
transcriptional cofactor p300. In concordance, we observed that Pecam1 and Acta2, 
which encode the blood vessel markers CD31 and α-SMA [45, 46], were induced in 
healthy animals 3 and 7 days after wounding after condensate application but less 
pronounced in diabetic animals. Released VEGF165 protein – a potent inducer of 
endothelial cell proliferation and recruitment [45] – seems to be rapidly diluted and 
degraded [36] and hardly affects Pecam1 expression levels. 
In line with the mRNA expression data, we found that HIF-1α delivery by PLL-g-
PEG nanocondensates resulted in an increased migration or proliferation of CD31 and 
α-SMA positive cells – that give rise to mature blood vessels – in control but not in 
diabetes type I resembling rats. However, we could not detect any increased mature 
blood vessel structures upon HIF-1α gene or VEGF protein delivery. Fibrin per se has 
wound healing properties [47] and it might be possible that fibrin masks the effect of 
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wound revascularization after HIF-1α gene delivery. Nevertheless, the elevated levels 
of endothelial cells and α-SMA positive cells suggest that the wounds respond with a 
preliminary angiogenic response to the polymer-DNA condensates without forming 
increased mature blood vessels structures at the time points of analyzes. However, 
due to the severe toxicity of STZ the experiment was always terminated at the latest 7 
days after wounding and no later time points were analyzed. In addition to blood 
vessel quantification, we measured the diameter of the blood vessels to predict the 
quality of the vascular network. In contrast to polyR-modified polymers, blood 
vessels of PLL-g-PEG and PLL-g-PEG-TG polymer treated wounds had a smaller 
average diameter than fibrin controls, suggesting that they faster developed an 
advanced capillary system. VEGF165 protein treatment caused a reduced capillary 
diameter in control animals, suggesting that it might be able to fine-tune the capillary 
network. However, this effect was abolished under hyperglycemic conditions and 
confirms other studies [45], where it was reported that VEGF might be 
disadvantageous for diabetic wound healing due to the formation of non-
physiologically leaky vessels, which can cause hemorrhage [48]. 
 
5. Conclusion 
PLL-g-PEG polymers condense plasmid DNA and can be functionalized with 
different peptides to modify their properties. The PLL-g-PEG dependent delivery of 
an oxygen-insensitive variant of HIF-1α in vivo successfully leads to differential gene 
expression and initiates an incipient angiogenic response in cutaneous wounds. 
However, we observed reduced effects in diabetic animals, possibly due to the 
hyperglycemia-dependent, reduced HIF-1α activity. Nanocondensates modified with 
polyR showed strongly improved transfection efficiency in vitro but not in vivo. In 
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fact, the inhibited wound contraction and the lack of capillary tuning indicate that it 
may even hinder wound healing under diabetic conditions. The wound milieu displays 
a much more complex environment and less controllable conditions than an in vitro 
assay and our results indicate that in vitro data have to be carefully considered since 
they do not necessarily predict the systemic environment of in vivo situations. It is 
convenient to establish and to test DNA delivering polymers or other systems in vitro 
but it is essential to verify these approaches in animal studies and to adapt them in 
order to match the requirements for a proper in vivo application. Furthermore, our 
diabetes model was toxin-induced and our studies had to be done on a narrow time 
frame, although diabetes is a chronic disease and may require long-term studies. 
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Tables 
 
Table 1. Nomenclature and abbreviation of the different PLL-g-PEG-DNA 
condensates 
Polymer DNA Nomenclature Label 
PLL-g-PEG pEGFP-N1 PLL-g-PEG/pEGFP-N1 -/GFP 
PLL-g-PEG-TG pEGFP-N1 PLL-g-PEG-TG/pEGFP-N1 TG/GFP 
PLL-g-PEG-polyR pEGFP-N1 PLL-g-PEG-polyR/pEGFP-N1 polyR/GFP 
PLL-g-PEG pHIF-1α−ΔODD PLL-g-PEG/pHIF-1α−ΔODD -/HIF 
PLL-g-PEG-TG pHIF-1α−ΔODD PLL-g-PEG-TG/pHIF-1α−ΔODD TG/HIF 
PLL-g-PEG-polyR pHIF-1α−ΔODD PLL-g-PEG-poyR/pHIF-1α−ΔODD polyR/HIF 
 
Table 2. Taq Man probes used for real-time PCR 
Gene Probe 
Rpl13a Rn00821946_g1 
Pecam1 (CD31) Rn01467262_m1 
Acta2 (SMA) Rn01759928_g1 
Vegf Rn01511601_m1 
 
Table 3. Primary Antibodies 
Target Name Supplier Dilution 
CD31 AF3628 R&D 1:500 
SMA ab5694 Abcam 1:500 
VEGF MAB293 R&D 1:400 
b-Actin ab8227 Abcam 1:1000 
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Figures 
Fig.1. Composition and structure of different PLL-g-PEG polymers. A PLL-g-PEG polymers consist of a 
20 kDa PLL backbone, which is grafted by PEG with a ratio ranging between 3 and 8%. Surface-
functionalized polymers carry peptides, namely TG and polyR, at the distal end of PEG. B Schematic 
view of PLL-g-PEG polymers with the lysine backbone (blue) consisting of 96 residues, the 5 kDa PEG 
residue (red) and both TG and polyR peptides (yellow) shows, that the peptides bind to PEG-maleimide 
via a the available sulfhydryl group of cysteine. 
 
Fig.2. Characterization of different PLL-g-PEG-DNA condensates. A The hydrodynamic diameter of 
different PLL-g-PEG polymers PLL-g-PEG/pEGFP (-/GFP), PLL-g-PEG-TG/pEGFP (TG/GFP) and PLL-
g-PEG-polyR/pEGFP (polyR/GFP) condensates was determined by dynamic light scattering and varied 
between 90 and 112 nm (n = 3). B The transfection efficiency of PLL-g-PEG-TG/pEGFP (TG/GFP) and 
PLL-g-PEG-polyR/pEGFP (polyR/GFP) condensates was assessed in COS-7 cells with different N/P 
ratios from 1 to 25 by normalizing to the transfection efficiency of unmodified PLL-g-PEG/pEGFP 
condensates (N/P 2.125); shown are means of triplicates ± Stdv. C The transfection efficiency of PLL-g-
PEG polymers PLL-g-PEG/pEGFP (-/GFP), PLL-g-PEG-TG/pEGFP (TG/GFP) and PLL-g-PEG-
polyR/pEGFP (polyR/GFP) condensates in COS-7 cell under normal (1 g/l) and high (4.5 g/l) glucose 
conditions. Values were normalized to -/GFP under normal conditions; shown are means of triplicates ± 
Stdv. D The cell viability was assessed for PLL-g-PEG polymers PLL-g-PEG/pEGFP (-/GFP), PLL-g-
PEG-TG/pEGFP (TG/GFP) and PLL-g-PEG-polyR/pEGFP (polyR/GFP) condensates in COS-7 cell 
using a WST-1 assay under normal (1 g/l) and high (4.5 g/l) glucose conditions. Values were normalized 
to untreated negative controls; shown are means of triplicates ± Stdv. 
 
Fig.3. In vitro DNA and nanocondensate release from 3D fibrin matrices. A The release of PLL-g-PEG (-
/GFP) and PLL-g-PEG-TG (TG/GFP) polymer-DNA condensates from 3D fibrin matrices was monitored 
for 7 days and PBS supernatant was removed and replaced in a 24-hour cycle The cumulative, relative 
values were obtained by adding the daily measured DNA content and normalizing them to the total DNA 
amount initially embedded within the fibrin matrix. Naked DNA served as a negative control; shown are 
means of triplicates ± Stdv. B The released DNA containing PLL-g-PEG (-/GFP) and PLL-g-PEG-TG 
(TG/GFP) condensates as well as released naked DNA in the daily isolated supernatant was used to 
transfect COS-7 cells. All values were normalized to non-embedded PLL-g-PEG/EGFP condensate-
controls containing 1 µg DNA; shown are means of triplicates ± Stdv. 
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Fig.4. Expression of HIF-1 target gene Vegf and the pro-angiogenic markers Pecam1 and Acta2 during 
in vivo wound healing. mRNA levels were determined 3 and 7 days post injury in wounds of normal 
(Mock) and diabetic (STZ) rats. Wounds were filled with either empty fibrin matrices (Fibrin – negative 
control), VEGF165 containing fibrin matrices (VEGF165 positive control) or with the different 
nanocondensates containing fibrin matrices: PLL-g-PEG/pHIF-1α-ΔODD (-/HIF), PLL-g-PEG-TG/pHIF-
1α-ΔODD (TG/HIF) and PLL-g-PEG-polyR/pHIF-1α-ΔODD (polyR/HIF). Rpl13a served as reference 
gene and expression levels were normalized to fibrin negative controls for each individual animal. 
Shown are means of 6 n ± SEM. Statistical validations were performed using a one-sample Wilcoxon 
signed rank test; * ≤ 0.05. 
 
Fig.5. Quantification of vascular structures during wound healing. Wounds of normal (Mock) and 
streptozotocin treated (STZ) rats were treated with fibrin only (negative control), with fibrin embedded 
VEGF165 (positive control) or with different fibrin embedded nanocondensates: PLL-g-PEG/pHIF-1α-
ΔODD (-/HIF), PLL-g-PEG-TG/pHIF-1α-ΔODD (TG/HIF) and PLL-g-PEG-polyR/pHIF-1α-ΔODD 
(polyR/HIF). A Shown are representative, centrally located sections of wound-cross-sections used for 
quantification 7 days after injury. Immunofluorescence staining indicates CD31 positive endothelial cells 
(red), a-SMA positive smooth muscle actin positive cells (green) and total number of cells (DAPI, blue). 
Scale bar: 250 µm. B Quantification of vascular structures and precursors in centrally located sections 
of wound-cross-sections 7 days after injury. Upper panel shows the number of positive CD31 
endothelial cells (left), a-SMA positive cells (middle) and CD31/SMA counts (right) normalized to the 
analyzed area. The lower panel represents the number of total cells (DAPI) per analyzed wound area 
(left) and the wound diameter (right). For all analyzes, values were normalized to fibrin negative controls 
for each animal and shown are means of triplicates ± SEM. Statistical validations were performed using 
a one-sample t- test; * ≤ 0.05. 
 
Fig.6. Estimation of the blood vessel diameter during wound healing in normal (Mock) and diabetic 
(STZ) rats 7 days after injury. The vessel diameter was measured in the central region of wound-cross-
sections either treated with fibrin only (negative control), with fibrin embedded VEGF165 (positive control) 
or with different fibrin embedded nanocondensates: PLL-g-PEG/pHIF-1α-ΔODD (-/HIF), PLL-g-PEG-
TG/pHIF-1α-ΔODD (TG/HIF) and PLL-g-PEG-polyR/pHIF-1α-ΔODD (polyR/HIF). A Shown are 
representative histograms of two individual rats (Mock vs. diabetic) and the distribution of the blood 
vessel diameter in the differently treated wounds. The x-axis represents the blood vessel size from 1 µm 
to 19 µm plus the last bar summarizing all vessels with a size of 20 or more µm. The relative blood 
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vessel amount was determined with “number of vessels per group” over “total number of analyzed blood 
vessels” (approximately 90 -150 per wound). B Shown is the mean of the average blood vessel 
diameter of 3 individual rats ± Stdv. Statistical validations were performed using a t- test comparing 
samples of both groups (Mock and STZ) against their respective fibrin negative control; * ≤ 0.05. 
	   34	  
 
 
 
	   35	  
 
 
	   36	  
 
 
	   37	  
 
 
 
	   38	  
 
 
	   39	  
 
 
